tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Ascentage Pharma Advances 2022 RSU Scheme with Share Purchase

Story Highlights
Ascentage Pharma Advances 2022 RSU Scheme with Share Purchase

Elevate Your Investing Strategy:

An announcement from Ascentage Pharma Group International ( (HK:6855) ) is now available.

Ascentage Pharma Group International announced the purchase of 50,000 shares by the Trustee for the 2022 RSU Scheme, representing approximately 0.014% of the total issued shares. This move is part of the company’s ongoing efforts to satisfy the RSUs upon exercise, reflecting its commitment to employee incentives and aligning with its strategic goals.

More about Ascentage Pharma Group International

Ascentage Pharma Group International is a biopharmaceutical company incorporated in the Cayman Islands, focusing on developing therapies for cancer, hepatitis B, and age-related diseases. The company is listed on the Hong Kong Stock Exchange and is involved in the research and development of novel small-molecule drugs.

YTD Price Performance: -25.96%

Average Trading Volume: 4,105,598

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$15.68B

Find detailed analytics on 6855 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1